Cause and metabolic consequences of fatty liver

Cause and metabolic consequences of fatty liver. Hyperglycemia and hyperinsulinemia induce hepatic de novo lipogenesis via carbohydrate response element–binding protein (ChREBP) and sterol regulatory element–binding protein (SREBP)-1c, respectively, thereby increasing the hepatic pool of fatty acyl-CoAs. This pool is also increased by augmented delivery of free fatty acids (FFAs) either through the diet or lipolysis in adipose tissue. Fatty acyl-CoAs are assembled to TAGs that remain in the liver or are secreted in the form of VLDLs. The latter pathway is regulated by several factors, among them the two enzymes SCD1 and DGAT2 as well as the microsomal transfer protein (MTP) and the availability of apoliprotein B (ApoB). ELOVL6 and PNPLA3/adiponutrin are also involved in the process of hepatic TAG storage, while specific mechanisms of action are not fully understood. Finally, a low activity of the ATGL also results in storage of fatty acyl-CoAs in the form of TAGs, thereby contributing to the detoxification of hepatic lipids. This process can also be accelerated by hepatic oxidation of fatty acyl-CoAs involving the transcription factors PPAR-α and -δ. In addition, the AMP-activated kinase (AMPK) is involved. The adipokine adiponectin stimulates FA oxidation via AMPK activation and PPAR-α induction. AMPK is also involved in the suppression of lipogenesis. When these mechanisms of detoxification are overwhelmed or not active, lipotoxicity prevails resulting in hepatic inflammation and insulin resistance. Via dysregulation of secreted hepatokines (e.g., fetuin-A, SHBG, selenoprotein P), increased glucose production and dyslipidemia, fatty liver then also induces systemic subclinical inflammation, whole-body insulin resistance, hyperglycemia, and ultimately the manifestation of type 2 diabetes and cardiovascular disease.
Cause and metabolic consequences of fatty liver

Publication

The Metabolically Benign and Malignant Fatty Liver. (2011) Norbert Stefan, et al. Diabetes. 2011 Aug;60(8):2011-2017. Figure: F4.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates DGAT2 DGAT2 ncbigene_symbol DGAT2 84649
Homo sapiens Primates SCD1 SCD1 ncbigene_synonym SCD 6319
Homo sapiens Primates ELOVL6 ELOVL6 ncbigene_symbol ELOVL6 79071
Homo sapiens Primates PPARA PPARA ncbigene_symbol PPARA 5465
Homo sapiens Primates AMPK AMPK ncbigene_synonym PRKAA1 5562
Homo sapiens Primates AMPK AMPK ncbigene_synonym PRKAA2 5563
Homo sapiens Primates AMPK AMPK ncbigene_synonym PRKAB1 5564
Homo sapiens Primates AMPK AMPK famplex_relations PRKAB2 5565
Homo sapiens Primates AMPK AMPK famplex_relations PRKAG1 5571
Homo sapiens Primates AMPK AMPK famplex_relations PRKAG2 51422
Homo sapiens Primates AMPK AMPK famplex_relations PRKAG3 53632
Homo sapiens Primates TAG TAG ncbigene_synonym TMED7 51014
Homo sapiens Primates TAG TAG ncbigene_synonym LINC01194 404663
Homo sapiens Primates ATGL ATGL ncbigene_synonym PNPLA2 57104
Homo sapiens Primates MTP MTP ncbigene_synonym MT1B 4490
Homo sapiens Primates MTP MTP ncbigene_synonym MTTP 4547
Homo sapiens Primates CHREBP CHREBP ncbigene_synonym MLXIPL 51085
Homo sapiens Primates ApoB APOB ncbigene_symbol APOB 338
Homo sapiens Primates SHBG SHBG ncbigene_symbol SHBG 6462

Chemical mentions

Word Match MeSH Name ChEBI
acyl-CoA NA mesh:D000214
Fructose Fructose mesh:D005632 fructose chebi:28757
Glucose Glucose mesh:D005947 D-glucopyranose chebi:4167

Disease mentions

Word Match MeSH Name DOID